{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-027756","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.021702+00:00","generated_at":"2026-06-12T04:59:56.606864+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Prime Medicine Q2 net loss $42.4M; cash $221.1M; Cimeio partnership","bullets":["Net loss of $42.4M for Q2 2023 vs $29.3M in Q2 2022; R&D expenses $34.6M (+83% YoY).","Cash, equivalents and investments $221.1M as of June 30, 2023; runway into 2025.","Entered research collaboration with Cimeio Therapeutics to develop shielded cell therapies for genetic diseases.","PM359 for chronic granulomatous disease advancing; IND-enabling studies expected in 2023.","First IND filing anticipated as early as 2024; additional filings in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-027756","json":"https://secwatch.observer/filing/0001628280-23-027756.json","markdown":"https://secwatch.observer/filing/0001628280-23-027756.md","text":"https://secwatch.observer/filing/0001628280-23-027756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828023027756/0001628280-23-027756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828023027756/prme-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:59:56.606864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1369b8ea5e2679c26b28393ba484eeba1574fda0","claim":"Prime Medicine, Inc. reported second quarter ended June 30, 2023 results: net income Net loss was $42.4 million for the three months ended June 30, 2023.","evidence_excerpt":"Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828023027756/0001628280-23-027756-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $42.4 million for the three months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}